INVESTIGADORES
MOLLERACH Marta Eugenia
congresos y reuniones científicas
Título:
Streptococcus pneumoniae: serotype and antibiotic resistance in isolates recovered from adult patients in an Argentinian teaching hospital
Autor/es:
OCAMPO P; KOVACEC V; BONOFIGLIO L; PERAZZI B; LOSADA M; GARCÍA S; PULIDO L; VAY C; LUNA CARLOS; MOLLERACH M; FAMIGLIETTI A
Lugar:
Valencia
Reunión:
Congreso; 7th Congress of European Microbiologists; 2017
Institución organizadora:
Federation of European Microbiological Societies
Resumen:
Background S. pneumoniae (Spn) is a major cause of morbi-mortality worldwide. Data regarding serotype distribution and its association with antibiotic resistance is scarce.The aim was to determine the serotype and antimicrobial susceptibility of Spn isolated from adult-patients that were attendant at Hospital de Clínicas, University of Buenos Aires and to evaluate the theorical coverage (TC) of PCV13 and PPSV23 vaccines.Methods:Spn isolates were collected from patients >18 y.o. in two periods 2010-2012 (1P) and 2013-2014 (2P). Serotype was performed by PCR (CDC). MIC determination was done by the BD-Phoenix-?-System.Results: 86 Spn isolates were recovered, 46 belonged from 1P and 40 from 2P. All isolates except two were recovered from non-meningeal sites. 26 serotypes were identified: main 1P serotypes were S14(26%), S6(13%), S17F(13%), S19F(11%), S19A(8.7%) and S22(6.5%); from 2P were S17F(12.5%), S7F(10%), S6(7.5%) and 22F(7.5%).The TC for PCV13/PPSV23 was 59/84.6% respectively. There was a significantly decreased of the TC between both periods for both vaccines (p= 0.01). Overall, 35%(1P) and 45%(2P) of isolates were penicillin non-susceptible, most were serotypes 19A, 14, 6 and 17F. The resistance for 1P and 2P was: erythromycin(30 and 33%), clindamycin(13 and 13%), tetracycline(28 and 20%) and TMS(35 and 20%). All strains were susceptible to amoxicillin, ceftriaxone, meropenem, levofloxacin, linezolid and vancomycin. Conclusions: A continuous surveillance program of serotypes and resistance in our Hospital is mandatory to predict treatment and monitor change in vaccine coverage since our results are different to those reported in our country.